Natural ergot alkaloids in ocular pharmacotherapy: known molecules for novel nanoparticle-based delivery systems

dc.commentsCEB53802por
dc.contributor.authorBaldim, Iarapor
dc.contributor.authorOliveira, Wanderley P.por
dc.contributor.authorKadian, Varshapor
dc.contributor.authorRao, Rekhapor
dc.contributor.authorYadav, Niteshpor
dc.contributor.authorMahant, Sheefalipor
dc.contributor.authorLucarini, Massimopor
dc.contributor.authorDurazzo, Alessandrapor
dc.contributor.authorDa Ana, Raquelpor
dc.contributor.authorCapasso, Raffaelepor
dc.contributor.authorSouto, Selma B.por
dc.contributor.authorSantini, Antonellopor
dc.contributor.authorSouto, Eliana B.por
dc.date.accessioned2020-07-07T10:06:20Z
dc.date.available2020-07-07T10:06:20Z
dc.date.issued2020-06-30
dc.date.updated2020-07-04T11:05:08Z
dc.description.abstractSeveral pharmacological properties are attributed to ergot alkaloids as a result of their antibacterial, antiproliferative, and antioxidant effects. Although known for their biomedical applications (e.g., for the treatment of glaucoma), most ergot alkaloids exhibit high toxicological risk and may even be lethal to humans and animals. Their pharmacological profile results from the structural similarity between lysergic acid-derived compounds and noradrenalin, dopamine, and serotonin neurotransmitters. To reduce their toxicological risk, while increasing their bioavailability, improved delivery systems were proposed. This review discusses the safety aspects of using ergot alkaloids in ocular pharmacology and proposes the development of lipid and polymeric nanoparticles for the topical administration of these drugs to enhance their therapeutic efficacy for the treatment of glaucoma.por
dc.description.publicationversioninfo:eu-repo/semantics/publishedVersion
dc.description.sponsorshipThis work was supported by CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) granted to I.B. (88887.368385/2019-00), by the Portuguese Science and Technology Foundation (FCT) and co-financed by FEDER, under the Partnership Agreement PT2020, granted to E.B.S. (UIDB/04469/2020 strategic fund), by the Nutraceutica come supporto nutrizionale nel paziente oncologico, project granted to A.S. (CUP: B83D18000140007), and by Foundation of Research Support of the São Paulo State (FAPESP) for the funded projects 2011/10333-1, 2012/03427-2, and 2018/26069-0 and for the National Council for Scientific and Technological Development (CNPq) granted to W.P.O.por
dc.distributioninternationalpor
dc.identifier.citationBaldim, Iara; Oliveira, Wanderley P.; Kadian, Varsha; Rao, Rekha; Yadav, Nitesh; Mahant, Sheefali; Lucarini, Massimo; Durazzo, Alessandra; Da Ana, Raquel; Capasso, Raffaele; Souto, Selma B.; Santini, Antonello; Souto, Eliana, Natural ergot alkaloids in ocular pharmacotherapy: known molecules for novel nanoparticle-based delivery systems. Biomolecules, 10(7), 980, 2020por
dc.identifier.doi10.3390/biom10070980por
dc.identifier.eissn2218-273Xpor
dc.identifier.issn2218-273Xpor
dc.identifier.pmid32630018por
dc.identifier.urihttps://hdl.handle.net/1822/65855
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)por
dc.relationUIDB/04469/2020por
dc.relation.publisherversionhttps://www.mdpi.com/journal/biomoleculespor
dc.rightsopenAccesspor
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/por
dc.subjectergot alkaloidspor
dc.subjectocular pharmacologypor
dc.subjectglaucomapor
dc.subjectlipid nanoparticlespor
dc.subjectpolymeric nanoparticlespor
dc.subject.wosScience & Technologypor
dc.titleNatural ergot alkaloids in ocular pharmacotherapy: known molecules for novel nanoparticle-based delivery systemspor
dc.typearticle
dspace.entity.typePublicationen
oaire.citationEndPage21por
oaire.citationIssue7por
oaire.citationStartPage1por
oaire.citationVolume10por
oaire.versionVoRpor
sdum.journalBiomoleculespor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
document_53802_1.pdf
Tamanho:
4.18 MB
Formato:
Adobe Portable Document Format